Sam is a trader and one of our lead stock analysts at AskTraders. After starting his career predominantly in the forex markets, Sam now focuses on gold and stocks with a preference for macroeconomic analysis.
Biotechnology company Immutep (NASDAQ: IMMP) has announced encouraging interim data from its ongoing Phase 2 TACTI-002.
The company released an update on Thursday evening stating that they were encouraged by the results of the study which is being conducted with Merck & Co Inc.
The study is evaluating the combination of Immutep’s lead product eftilagimod alpha with Merck’s KEYTRUDA in patients with 2nd line head and neck squamous cell carcinoma or non-small cell lung cancer.
“We are very encouraged by the results in this patient group with resistant late stage Head & Neck Cancers where the likelihood of response to other treatments is small.
“The durability of responses and the two patients with a complete response are extremely promising signals and this combination should be further investigated,” said the Principal investigator, Dr Martin Forster, University College London Hospital.
The news has seen Immutep’s US-listed stock price significantly increase premarket on Friday. Having closed Thursday’s trading session at $1.60, it is currently trading 10.62% higher at $1.77 ahead of the open.
PEOPLE WHO READ THIS ALSO VIEWED:
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage . 75 % of retail investor accounts lose money when trading CFDs with this provider . You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money .